bpc 157 or BPC-157 Injectable Peptide for Healing & Recovery The Hidden Risks of BPC‑157:

In addition, while a number of the agonists in Table 1 (Families 2-5) have norleucine at Rj, or an amino acid residue, in the practice of various embodiments of this invention a number of an amino acid residues (D or L) may be used at residue Ri, including without limitation, tyrosine, phenylalanine, aspartic acid, arginine, isoleucme, serine, histidine, glycine, cysteine, methionine, tryptophan, norvaline, ornithine, S-benzyl cysteine amino acid residues

BPC-157 is not explicitly named on the World Anti-Doping Agency (WADA) prohibited list, unlike TB-500 which is explicitly banned

All information is provided for educational and scientific reference only

Journal of Medicinal Chemistry, 57 (22), 9220